225 related articles for article (PubMed ID: 12813467)
1. Phospholipase D confers rapamycin resistance in human breast cancer cells.
Chen Y; Zheng Y; Foster DA
Oncogene; 2003 Jun; 22(25):3937-42. PubMed ID: 12813467
[TBL] [Abstract][Full Text] [Related]
2. Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Chen Y; Rodrik V; Foster DA
Oncogene; 2005 Jan; 24(4):672-9. PubMed ID: 15580312
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.
Paglin S; Lee NY; Nakar C; Fitzgerald M; Plotkin J; Deuel B; Hackett N; McMahill M; Sphicas E; Lampen N; Yahalom J
Cancer Res; 2005 Dec; 65(23):11061-70. PubMed ID: 16322256
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
8. Regulation of mTOR by phosphatidic acid?
Foster DA
Cancer Res; 2007 Jan; 67(1):1-4. PubMed ID: 17210675
[TBL] [Abstract][Full Text] [Related]
9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels.
Ghayad SE; Bieche I; Vendrell JA; Keime C; Lidereau R; Dumontet C; Cohen PA
Cancer Sci; 2008 Oct; 99(10):1992-2003. PubMed ID: 19016759
[TBL] [Abstract][Full Text] [Related]
11. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK; Yang X; Thor AD; Somasundaram K
Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
[TBL] [Abstract][Full Text] [Related]
12. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
14. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
[TBL] [Abstract][Full Text] [Related]
15. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidic acid-mediated mitogenic activation of mTOR signaling.
Fang Y; Vilella-Bach M; Bachmann R; Flanigan A; Chen J
Science; 2001 Nov; 294(5548):1942-5. PubMed ID: 11729323
[TBL] [Abstract][Full Text] [Related]
18. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
Gadir N; Jackson DN; Lee E; Foster DA
Oncogene; 2008 Feb; 27(8):1055-62. PubMed ID: 17700525
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.
Hui L; Zheng Y; Yan Y; Bargonetti J; Foster DA
Oncogene; 2006 Nov; 25(55):7305-10. PubMed ID: 16785993
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
